Literature DB >> 31177870

Circulating Resistin Is Associated with Plasma Glucagon-Like Peptide-1 in Cirrhotic Patients with Hepatitis C Virus Genotype-4 Infection.

Doaa M Ibrahim1, El Saeid E Shaaban2, Tarek A Fouad2.   

Abstract

Purpose: Limited and contradictory data on the circulating levels of glucagon-like peptide (GLP-1) and resistin in hepatitis C virus genotype-4 (HCV-4) cirrhotic patients are present. Thus, this study aimed to evaluate their concentrations and to investigate the association between total GLP-1, resistin, and insulin resistance in those patients.Materials and
Methods: Non-diabetic HCV-4 cirrhotic patients (n = 80; 40 with Child-Pugh A, 20 with Child-Pugh B, and 20 with Child-Pugh C), and 25 healthy subjects were enrolled in this study. The basal circulating levels of total GLP-1 and resistin along with serum insulin, glucose, total cholesterol, and triglycerides were measured.
Results: Plasma GLP-1 and serum resistin levels were significantly higher in cirrhotic patients than controls (P < . 001). Moreover, circulating GLP-1 and resistin levels increased in a stepwise fashion in line with increasing grade of liver damage. According to Spearman's rank correlation, both GLP-1 and resisitin correlated positively with each other, insulin, homeostatic model assessment of insulin resistance, alanine aminotransferase (ALT), total bilirubin, and international normalized ratio while they correlated negatively with albumin (P < .001). Multiple stepwise regression analysis showed that ALT, serum resistin and Child-Pugh score independently influenced the GLP-1 levels in cirrhotic patients.Conclusions: Circulating levels of GLP-1 and resistin were elevated in cirrhotic patients with HCV-4. Further, the severity of liver cirrhosis and serum resistin were the determinant factors explaining the variability of GLP-1 levels by about 84%. In addition, a positive relation was found between insulin resistance and both GLP-1 and resistin levels.

Entities:  

Keywords:  GLP-1; HCV genotype-4; Resistin; cirrhosis

Mesh:

Substances:

Year:  2019        PMID: 31177870     DOI: 10.1080/07435800.2019.1627551

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  3 in total

1.  MiR-625 Inhibits Tumor Cell Invasion, Migration and EMT by Negatively Regulating the Expression of Resistin in Non-Small Cell Lung.

Authors:  Yongsheng Zhao; Renyan Zheng; Dong Ning; Fei Xie
Journal:  Cancer Manag Res       Date:  2020-06-03       Impact factor: 3.989

Review 2.  Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.

Authors:  Ming-Ling Chang; Zinger Yang; Sien-Sing Yang
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

Review 3.  Impact of Incretin-Based Therapies on Adipokines and Adiponectin.

Authors:  Habib Yaribeygi; Mina Maleki; Stephen L Atkin; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-10-07       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.